TP53 and lung carcinoma: 13C6-glucose and 13C5,15N2-Gln-based SIRM studies revealed different metabolic mechanisms that underlie the differential sensitivity of lung cancer cells (A549 cells with WT p53 and p53-null H1299 cells) to the three Se agents.